Virtual care company Omada Health on Thursday said it will start prescribing GLP-1s and other obesity drugs and helping patients manage those medications. Omada plans to expand the offerings under its weight management program as its membership grows to more than 800,000. The announcement comes as digital health companies increase their presence in the blockbuster market for GLP-1s to treat obesity, diabetes and other chronic conditions – a space that could be worth roughly $100 billion by the